Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 + Venetoclax (Standard vs Shorter Duration) in AML
NCT07437950Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2026
- Primary completion
- Sep 2034
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Sep 2026; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07437950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07437950.